The Summary of Product Characteristics (SPC) for warfarin advises that genetic variability, particularly in relation to CYP2C9 and VKORC1 can significantly affect the dose requirements for warfarin and that if a family association with these polymorphisms is known then extra care is warranted during initiation and early titration.